We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
- Recent MDT Stock Price: $78.37
- Yearly Gain for MDT stock: 2.58%
- Market Cap for MDT stock: $104.61B
- P/E Ratio for MDT stock: 25.546
Will MDT's stock price go up? Is there an accurate MDT stock forecast available?
TipRanks.com reports that Medtronic currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $84.20. The target pricing ranges from a high MDT forecast of $89 down to a low forecast of $79. Medtronic (MDT)’s last closing stock price was $78.37 which would put the average price target at 12.63% upside.
In addition, TradingView issued a Buy rating for MDT stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on MDT stock.
Other analysts covering MDT include:
- Steven Lichtman of Oppenheimer issued a Hold rating with the price target of $89 on 1 day ago
- Robbie Marcus of J.P. Morgan issued a Hold rating with the price target of $82 on 1 day ago
- Matthew O'Brien of Piper Sandler issued a Hold rating with the price target of $87 on 1 day ago
- Pito Chickering of Deutsche Bank issued a Hold rating with the price target of $79 on 1 day ago
If you are wondering if MDT is a good stock to buy, here are 3rd party ratings for MDT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 43% (142 out of 251)
What is the sentiment on the street regarding Medtronic? (Current ratings compiled by TipRanks.com)
- News Sentiment for MDT stock: Very Bullish
- Blogger Consensus for MDT stock: Bullish
- Media Buzz for MDT stock: Very High
- Insider Signal for MDT stock: Negative
- Investor Sentiment for MDT stock: Positive
- Hedge Fund signal for MDT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on MDT stock including scouring the social networks like MDT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MDT stock chart >>
Summary: Agilent Technologies, Inc. is an original equipment manufacturer of a broad-based portfolio of test and measurement products serving multiple end markets. Recently, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers' representatives, telesales and electronic commerce, as necessary.
- Recent A Stock Price: $123.99
- Yearly Gain for A stock: -19.62%
- Market Cap for A stock: $36.26B
- P/E Ratio for A stock: 29.575
Will A's stock price go up? Is there an accurate A stock forecast available?
TipRanks.com reports that Agilent currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $128.00. The target pricing ranges from a high A forecast of $145 down to a low forecast of $100. Agilent (A)’s last closing stock price was $123.99 which would put the average price target at 7.00% upside.
In addition, TradingView issued a Buy rating for A stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on A stock.
Other analysts covering A include:
- Derik De Bruin of Bank of America Securities issued a Buy rating with the price target of $130 on 2 days ago
- Luke Sergott of Barclays issued a Sell rating with the price target of $100 on 2 days ago
- Daniel Arias of Stifel Nicolaus issued a Hold rating with the price target of $135 on 2 days ago
- Catherine Ramsey Schulte of Robert W. Baird issued a Buy rating with the price target of $130 on 3 days ago
If you are wondering if A is a good stock to buy, here are 3rd party ratings for A stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 37% (92 out of 251)
What is the sentiment on the street regarding Agilent? (Current ratings compiled by TipRanks.com)
- News Sentiment for A stock: Very Bullish
- Blogger Consensus for A stock: Bullish
- Media Buzz for A stock: Very High
- Insider Signal for A stock: ―
- Investor Sentiment for A stock: Negative
- Hedge Fund signal for A stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on A stock including scouring the social networks like A StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for A stock chart >>
Summary: Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
- Recent ENTA Stock Price: $8.99
- Yearly Gain for ENTA stock: -80.02%
- Market Cap for ENTA stock: $209.92M
- P/E Ratio for ENTA stock: -1.41
Will ENTA's stock price go up? Is there an accurate ENTA stock forecast available?
TipRanks.com reports that Enanta Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $25.20. The target pricing ranges from a high ENTA forecast of $40 down to a low forecast of $14. Enanta Pharmaceuticals (ENTA)’s last closing stock price was $8.99 which would put the average price target at 161.40% upside.
In addition, TradingView issued a sell rating for ENTA stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ENTA stock.
Other analysts covering ENTA include:
- Ed Arce of H.C. Wainwright issued a Buy rating with the price target of $28 on 2 days ago
- Roy Buchanan of JMP Securities issued a Buy rating with the price target of $23 on 2 days ago
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $40 on 3 days ago
- Roanna Ruiz of Leerink Partners issued a Hold rating with the price target of $14 on 3 days ago
If you are wondering if ENTA is a good stock to buy, here are 3rd party ratings for ENTA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 24% (60 out of 251)
What is the sentiment on the street regarding Enanta Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ENTA stock: Very Bullish
- Blogger Consensus for ENTA stock: ―
- Media Buzz for ENTA stock: Medium
- Insider Signal for ENTA stock: ―
- Investor Sentiment for ENTA stock: ―
- Hedge Fund signal for ENTA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ENTA stock including scouring the social networks like ENTA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ENTA stock chart >>
Summary: MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.
- Recent MDWD Stock Price: $8.70
- Yearly Gain for MDWD stock: -24.68%
- Market Cap for MDWD stock: $77.33M
- P/E Ratio for MDWD stock: -2.547
Will MDWD's stock price go up? Is there an accurate MDWD stock forecast available?
TipRanks.com reports that Mediwound currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.00. The target pricing ranges from a high MDWD forecast of $36 down to a low forecast of $25. Mediwound (MDWD)’s last closing stock price was $8.70 which would put the average price target at 191.15% upside.
In addition, TradingView issued a Buy rating for MDWD stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MDWD stock.
Other analysts covering MDWD include:
- Michael Okunewitch of Maxim Group issued a Buy rating with the price target of $25 on 1 day ago
- Josh Jennings of TD Cowen issued a Buy rating with the price target of $25 on 2 days ago
- Francois Brisebois of Oppenheimer issued a Buy rating with the price target of $36 on 3 months ago
If you are wondering if MDWD is a good stock to buy, here are 3rd party ratings for MDWD stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 24% (60 out of 251)
What is the sentiment on the street regarding Mediwound? (Current ratings compiled by TipRanks.com)
- News Sentiment for MDWD stock: Very Bullish
- Blogger Consensus for MDWD stock: Bullish
- Media Buzz for MDWD stock: High
- Insider Signal for MDWD stock: ―
- Investor Sentiment for MDWD stock: Very Negative
- Hedge Fund signal for MDWD stock: Neutral
The stock market is extremely volatile, and you need to do your own research on MDWD stock including scouring the social networks like MDWD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MDWD stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
